Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Active Biotech AB (publ) is a Swedish biotechnology firm focused on developing pharmaceutical treatments for oncology and immunological conditions. Its product pipeline features Tasquinimod, a small molecule immunomodulator currently in Phase Ib/IIa clinical trials for treating multiple myeloma. Another key asset is Laquinimod, an immunomodulator undergoing Phase I development for various inflammatory eye disorders, including uveitis. Additionally, the company is advancing Naptumomab, an anti-cancer immunotherapy, which is in Phase Ib/II clinical trials for individuals with advanced solid tumors. Naptumomab's development and commercialization are managed through a licensing partnership with NeoTX Therapeutics Ltd. Founded in 1983, Active Biotech AB (publ) is headquartered in Lund, Sweden.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.